Atrial fibrillation: Difference between revisions
| Line 47: | Line 47: | ||
===Anticoagulation=== | ===Anticoagulation=== | ||
[[Atrial fibrillation anticoagulation|Anticoagulation Overview]] | [[Warfarin | [[Atrial fibrillation anticoagulation|Anticoagulation Overview]] | [[Warfarin]] | [[Dabigatran#Converting from or to Warfarin|Converting from or to Warfarin]] | [[Dabigatran#Converting from or to Parenteral Anticoagulants|Converting from or to Parenteral Anticoagulants]] | [[Dabigatran]] | ||
=====Dabigatran===== | =====Dabigatran===== | ||
[[dabigatran#Dosing|Dosing]] | [[Dabigatran#Surgery and Interventions|Discontinuation for Surgery and Interventions]] | [[Dabigatran#WARNINGS AND PRECAUTIONS| Warnings and Precautions]] | [[Dabigatran#Adverse Reactions|Adverse Reactions]] | [[Dabigatran#Use in Specific Populations|Use in Specific Populations Such as Pregnancy]] | [[Dabigatran#Overdosage|Overdosage]] | [[Clinical Pharmacology of Dabigatran|Clinical Pharmacology]] | [[FDA Review of Data From the RE-LY Trial on September 20th, 2010|FDA Review of the RE-LY Data]] | [[A comparison of the RE-LY and Rocket AF Trials ]] | [[Estimates of Cost Per Year of Life Saved for Dabigatran]] | [[dabigatran#Dosing|Dosing]] | [[Dabigatran#Surgery and Interventions|Discontinuation for Surgery and Interventions]] | [[Dabigatran#WARNINGS AND PRECAUTIONS| Warnings and Precautions]] | [[Dabigatran#Adverse Reactions|Adverse Reactions]] | [[Dabigatran#Use in Specific Populations|Use in Specific Populations Such as Pregnancy]] | [[Dabigatran#Overdosage|Overdosage]] | [[Clinical Pharmacology of Dabigatran|Clinical Pharmacology]] | [[FDA Review of Data From the RE-LY Trial on September 20th, 2010|FDA Review of the RE-LY Data]] | [[A comparison of the RE-LY and Rocket AF Trials ]] | [[Estimates of Cost Per Year of Life Saved for Dabigatran]] | ||
Revision as of 14:32, 6 November 2012
| Atrial fibrillation | |
| ICD-10 | I48 |
|---|---|
| ICD-9 | 427.31 |
| DiseasesDB | 1065 |
| MedlinePlus | 000184 |
|
Atrial Fibrillation Microchapters | |
|
Special Groups | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Cardioversion | |
|
Anticoagulation | |
|
Surgery | |
|
Case Studies | |
|
Atrial fibrillation On the Web | |
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and related keywords: AF; afib; fib; PAF; paroxysmal afib; lone fibrillator
Overview
Classification
Pathophysiology
Causes
Differentiating Atrial fibrillation from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Special Groups
Postoperative AF | Acute Myocardial Infarction | Wolff-Parkinson-White Preexcitation Syndromes | Hypertrophic Cardiomyopathy | Hyperthyroidism | Pulmonary Diseases | Pregnancy
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | EKG Examples | Afib with LBBB EKG Examples | Chest X Ray | Echocardiography | Holter monitoring | Cardiac MRI | Exercise stress testing
Treatment
Cardioversion
Cardioversion Overview | Electrical Cardioversion | Pharmacological Cardioversion
Anticoagulation
Anticoagulation Overview | Warfarin | Converting from or to Warfarin | Converting from or to Parenteral Anticoagulants | Dabigatran
Dabigatran
Dosing | Discontinuation for Surgery and Interventions | Warnings and Precautions | Adverse Reactions | Use in Specific Populations Such as Pregnancy | Overdosage | Clinical Pharmacology | FDA Review of the RE-LY Data | A comparison of the RE-LY and Rocket AF Trials | Estimates of Cost Per Year of Life Saved for Dabigatran
Rate control
Maintenance of Sinus Rhythm
Surgical options
Radiofrequency ablation | Maze Open Heart Surgery
Secondary Prevention
Supportive Trial Data
Related Chapters
de:Vorhofflimmern it:Fibrillazione atriale nl:Boezemfibrilleren no:Atrieflimmer fi:Eteisvärinä